Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (3) : 629-641     DOI: 10.14336/AD.2019.0613
Orginal Article |
Lactulose Suppresses Osteoclastogenesis and Ameliorates Estrogen Deficiency-Induced Bone Loss in Mice
Chen Xiao1, Zhang Zheng2, Hu Yan1, Cui Jin1, Zhi Xin2, Li Xiaoqun2, Jiang Hao1, Wang Yao1, Gu Zhengrong3, Qiu Zili4, Dong Xin5, Li Yuhong1, Su Jiacan1,2,*
1Department of Orthopedics Trauma, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
2College of Basic Medicine, Second Military Medical University, Shanghai, China.
3Department of Orthopedics, Jing’ An District Centre Hospital of Shanghai Huashan Hospital, Fudan University, Shanghai, China.
4Jinling high school, Nanjing, Jiangsu, China.
5School of Pharmacology, Second Military Medical University, Shanghai, China.
Download: PDF(1244 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

Postmenopausal osteoporosis is characterized by excess osteoclastogenesis which leads to net bone loss and brittle fractures. Studies have demonstrated that estrogen deficiency-associated bone loss is microbiota-dependent and could be prevented by probiotics and prebiotics. In this study, we report that orally administered lactulose (20 g/kg, 6 weeks) orally administered significantly inhibited osteoclastogenesis, bone resorption, and prevented ovariectomy (OVX)-induced bone loss in mice. Lactulose increased intestinal Claudin 2, 3 and 15, compared to the OVX group, and lowered pro-osteoclastogenic cytokines levels including tumor necrosis factor-α, interleukin(IL)-6, receptor activator of nuclear factor kappa-Β ligand (RANKL), and IL-17 as well as increased the anti-inflammatory cytokine IL-10 in the intestine, peripheral blood, and bone marrow. Lactulose significantly preserved the number of Foxp3+ Treg cells in the intestines compared with that in OVX mice. Lactulose altered the composition of intestinal microbiota measured by 16s rDNA sequencing and increased intestinal and serum short-chain fatty acids (SCFAs) levels including acetate, propionate and butyrate which were decreased in OVX mice as measured by gas chromatography. Oral administration of lactulose for 2 weeks significantly lowered the level of bone resorption marker C-telopeptide of type 1 collagen-1 in healthy male young volunteers (aging 20-25 years). In conclusion, lactulose inhibited osteoclastogenesis and bone resorption by altering the intestinal microbiota and increasing SCFAs. Lactulose could serve as an ideal therapeutic agent for postmenopausal osteoporosis.

Keywords lactulose      short-chain fatty acids      gut microbiota      postmenopausal osteoporosis      osteoclastogenesis     
Corresponding Authors: Su Jiacan   
About author:

These authors contributed equally to this work.

Just Accepted Date: 05 August 2019   Issue Date: 13 May 2020
E-mail this article
E-mail Alert
Articles by authors
Chen Xiao
Zhang Zheng
Hu Yan
Cui Jin
Zhi Xin
Li Xiaoqun
Jiang Hao
Wang Yao
Gu Zhengrong
Qiu Zili
Dong Xin
Li Yuhong
Su Jiacan
Cite this article:   
Chen Xiao,Zhang Zheng,Hu Yan, et al. Lactulose Suppresses Osteoclastogenesis and Ameliorates Estrogen Deficiency-Induced Bone Loss in Mice[J]. Aging and disease, 2020, 11(3): 629-641.
URL:     OR
Figure 1.  Lactulose prevented bone loss induced by ovariectomy in mice. (A) Representative μCT analysis of the distal femur. (B) Representative H&E staining of distal femoral sections and quantification of the trabecular area from each group 6 weeks after the operation of H&E staining. Scale bar: 200 μm. (C) Calculations of bone value / total value (BV/TV), bone surface area /total value (BS/TV), bone mineral density (BMD), trabecular number (Tb.N), bone surface area / bone value (BS/BV), trabecular space (Tb.Sp). Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding group.
Figure 2.  Lactulose suppressed osteoclastogenesis. (A) Tartrate-resistant acid phosphatase-stained sections of the distal femur. Scale bar: 20 μm. (B) Oc.N / B.Area. and Oc.N / (C) Serum levels of TRAcp-5b. (D) Osteocalcin stained sections of the distal femur. Original magnification ×40. Scale bar: 20 μm. (E) Ob.N / B.Area. and Ob.N / (F) Serum levels of osteocalcin. n= 5 mice per group in all panels. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding group.
Figure 3.  Lactulose reduced intestine permeability after OVX. (A) Transcript levels of the tight junction proteins claudin 2, claudin 3 and claudin 15 of Sham, OVX and OVX mice treated with lactulose in the small intestine. (B) Immunohistological analysis of claudin 2 expressions in small intestine of Sham, OVX and OVX mice treated with lactulose. (Scale bar: 200 or 20 μm). Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding group.
Figure 4.  Lactulose inhibited OVX-induced pro-inflammatory cytokines. (A) Levels of the inflammatory cytokines TNF-α, IL-6, RANKL, and IL-17 and anti-inflammatory cytokine IL-10 in the small intestine of Sham, OVX and OVX mice treated with lactulose. (B) Immunofluorescent analysis of Foxp3+ cells in the intestine from Sham, OVX and OVX mice treated with lactulose small. Scale bar: 20 μm. (C) Calculation of Foxp3+ cells/Area. n = 5 mice per group in all panels. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding group.
Figure 5.  Lactulose altered gut microbiota and increased SCFA production. (A) PCoA analysis. (B) Observed Species Number in different sequence number. (C) Ternary plot of different groups. (D) Taxonomy distribution at the genus level in different samples. (E) Top 10 enriched species in all groups. (F-I) Significantly differed species in the different groups; (J-L) The fecal SCFA levels of each group. (M) The serum SCFA levels of each group. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding group.
Figure 6.  Graphical abstract. Estrogen withdrawal results in reduced fecal SCFA, increased systemic pro-inflammatory cytokines levels, excessive osteoclastogenesis, and significant bone loss. Lactulose increases SCFA production, lowers osteoclastogenic cytokines levels, inhibits osteoclastogenesis and ameliorates bone loss.
[1] Loi F, Cordova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB (2016). Inflammation, fracture and bone repair. Bone, 86:119-130.
[2] Black DM (2016). Postmenopausal Osteoporosis (vol 374, pg 254, 2016). New England Journal of Medicine, 374:1797-1797.
[3] Osta B, Benedetti G, Miossec P (2014). Classical and Paradoxical Effects of TNF-alpha on Bone Homeostasis. Front Immunol, 5:48.
[4] Pacifici R (2012). Role of T cells in ovariectomy induced bone loss--revisited. J Bone Miner Res, 27:231-239.
[5] Chen X, Zhi X, Pan PP, Cui J, Cao LH, Weng WZ, et al. (2017). Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. Faseb Journal, 31:4855-4865.
[6] Miossec P, Korn T, Kuchroo VK (2009). Interleukin-17 and type 17 helper T cells. N Engl J Med, 361:888-898.
[7] Grassi F, Tell G, Robbie-Ryan M, Gao Y, Terauchi M, Yang X, et al. (2007). Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci U S A, 104:15087-15092.
[8] Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, et al. (2016). Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. Journal of Clinical Investigation, 126:2049-2063.
[9] Lucas S, Omata Y, Hofmann J, Bottcher M, Iljazovic A, Sarter K, et al. (2018). Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. Nat Commun, 9:55.
[10] Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L (2014). The role of short-chain fatty acids in health and disease. Adv Immunol, 121:91-119.
[11] Villa CR, Ward WE, Comelli EM (2017). Gut microbiota-bone axis. Crit Rev Food Sci Nutr, 57:1664-1672.
[12] Ait-Aissa A, Aider M (2014). Lactulose: production and use in functional food, medical and pharmaceutical applications. Practical and critical review. International Journal of Food Science and Technology, 49:1245-1253.
[13] Jia JD (2012). Lactulose in the treatment of hepatic encephalopathy: new evidence for an old modality. J Gastroenterol Hepatol, 27:1262-1263.
[14] Feng W, Liu H, Luo T, Liu D, Du J, Sun J, et al. (2017). Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-kappaB, ERK and JNK signaling pathways. Sci Rep, 7:41411.
[15] Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000). TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest, 106:1481-1488.
[16] Zhai X, Chen X, Shi J, Shi D, Ye Z, Liu W, et al. (2013). Lactulose ameliorates cerebral ischemia-reperfusion injury in rats by inducing hydrogen by activating Nrf2 expression. Free Radic Biol Med, 65:731-741.
[17] Chen X, Zhai X, Shi J, Liu WW, Tao H, Sun X, et al. (2013). Lactulose mediates suppression of dextran sodium sulfate-induced colon inflammation by increasing hydrogen production. Dig Dis Sci, 58:1560-1568.
[18] Chen X, Zuo Q, Hai Y, Sun XJ (2011). Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production. Med Hypotheses, 76:325-327.
[19] Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H, et al. (2017). Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis, 8:e3037.
[20] Koide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, et al. (2009). Diphenylhydantoin Inhibits Osteoclast Differentiation and Function Through Suppression of NFATc1 Signaling. Journal of Bone and Mineral Research, 24:1469-1480.
[21] Schumann C (2002). Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr, 41 Suppl 1:I17-25.
[22] Vemuri R, Gundamaraju R, Eri R (2017). Role of Lactic Acid Probiotic Bacteria in IBD. Curr Pharm Des, 23:2352-2355.
[23] Gluud LL, Vilstrup H, Morgan MY (2016). Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev:CD003044.
[24] Sakai Y (2018). [Milk, Daily products and Bone health.The effect of lactulose on bone health.]. Clin Calcium, 28:513-517.
[25] Van den Heuvel EG, Muijs T, Van Dokkum W, Schaafsma G (1999). Lactulose stimulates calcium absorption in postmenopausal women. J Bone Miner Res, 14:1211-1216.
[26] Brommage R, Binacua C, Antille S, Carrie AL (1993). Intestinal calcium absorption in rats is stimulated by dietary lactulose and other resistant sugars. J Nutr, 123:2186-2194.
[27] Beynen AC, Kappert HJ, Yu S (2001). Dietary lactulose decreases apparent nitrogen absorption and increases apparent calcium and magnesium absorption in healthy dogs. J Anim Physiol Anim Nutr (Berl), 85:67-72.
[28] Weitzmann MN, Pacifici R (2006). Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest, 116:1186-1194.
[29] Song H, Li X, Zhao Z, Qian J, Wang Y, Cui J, et al. (2019). Reversal of Osteoporotic Activity by Endothelial Cell-Secreted Bone Targeting and Biocompatible Exosomes. Nano Lett, 19:3040-3048.
[30] D'Amelio P, Grimaldi A, Di Bella S, Brianza SZM, Cristofaro MA, Tamone C, et al. (2008). Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone, 43:92-100.
[31] Adeel S, Singh K, Vydareny KH, Kumari M, Shah E, Weitzmann MN, et al. (2013). Bone loss in surgically ovariectomized premenopausal women is associated with T lymphocyte activation and thymic hypertrophy. J Investig Med, 61:1178-1183.
[32] Dou C, Ding N, Zhao C, Hou T, Kang F, Cao Z, et al. (2018). Estrogen Deficiency-Mediated M2 Macrophage Osteoclastogenesis Contributes to M1/M2 Ratio Alteration in Ovariectomized Osteoporotic Mice. J Bone Miner Res, 33:899-908.
[33] Masson L, Salkinder AL, Olivier AJ, McKinnon LR, Gamieldien H, Mlisana K, et al. (2015). Relationship between female genital tract infections, mucosal interleukin-17 production and local T helper type 17 cells. Immunology, 146:557-567.
[34] Molnar I, Bohaty I, Somogyine-Vari E (2014). IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis. Osteoporos Int, 25:783-786.
[35] DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, et al. (2012). IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem, 113:2895-2902.
[36] Tyagi AM, Mansoori MN, Srivastava K, Khan MP, Kureel J, Dixit M, et al. (2014). Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-alpha antibodies. J Bone Miner Res, 29:1981-1992.
[37] Chen X, Zhi X, Wang J, Su J (2018). RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation. Bone Res, 6:34.
[38] Dou C, Ding N, Luo F, Hou T, Cao Z, Bai Y, et al. (2018). Graphene-Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization. Adv Sci (Weinh), 5:1700578.
[39] Wu Q, Zhou X, Huang D, Ji Y, Kang F (2017). IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro. Cell Physiol Biochem, 41:1360-1369.
[40] Li JY, Yu M, Tyagi AM, Vaccaro C, Hsu E, Adams J, et al. (2018). IL-17 Receptor Signaling in Osteoblasts/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production. J Bone Miner Res, 34: 349-360.
[41] Kim YG, Lee CK, Nah SS, Mun SH, Yoo B, Moon HB (2007). Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem Biophys Res Commun, 357:1046-1052.
[42] Turner JR (2009). Intestinal mucosal barrier function in health and disease. Nat Rev Immunol, 9:799-809.
[43] Ahmad R, Sorrell MF, Batra SK, Dhawan P, Singh AB (2017). Gut permeability and mucosal inflammation: bad, good or context dependent. Mucosal Immunol, 10:307-317.
[44] Odenwald MA, Turner JR (2017). The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol, 14:9-21.
[45] Xu X, Jia X, Mo L, Liu C, Zheng L, Yuan Q, et al. (2017). Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis. Bone Res, 5:17046.
[46] Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, et al. (2016). Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest, 126:2049-2063.
[47] Cox-York KA, Sheflin AM, Foster MT, Gentile CL, Kahl A, Koch LG, et al. (2015). Ovariectomy results in differential shifts in gut microbiota in low versus high aerobic capacity rats. Physiol Rep, 3.
[48] Liu TW, Park YM, Holscher HD, Padilla J, Scroggins RJ, Welly R, et al. (2015). Physical Activity Differentially Affects the Cecal Microbiota of Ovariectomized Female Rats Selectively Bred for High and Low Aerobic Capacity. Plos One, 10.
[49] Chiu YH, Ritchlin CT (2016). DC-STAMP: A Key Regulator in Osteoclast Differentiation. J Cell Physiol, 231:2402-2407.
[50] Vanitallie TB (2013). Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. Metabolism, 62 Suppl 1:S30-33.
[51] Boyce BF (2013). Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res, 92:860-867.
[52] Harmer D, Falank C, Reagan MR (2018). Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front Endocrinol (Lausanne), 9:788.
[53] Boyle WJ, Simonet WS, Lacey DL (2003). Osteoclast differentiation and activation. Nature, 423:337-342.
[54] Chow J, Tang HQ, Mazmanian SK (2011). Pathobionts of the gastrointestinal microbiota and inflammatory disease. Current Opinion in Immunology, 23:473-480.
[55] Irwin R, Lee T, Young VB, Parameswaran N, McCabe LR (2013). Colitis-induced bone loss is gender dependent and associated with increased inflammation. Inflamm Bowel Dis, 19:1586-1597.
[56] Xu M, Pokrovskii M, Ding Y, Yi R, Au C, Harrison OJ, et al. (2018). c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont. Nature, 554:373-+.
[57] Chambers ES, Morrison DJ, Frost G (2015). Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? Proceedings of the Nutrition Society, 74:328-336.
[58] Xu Y, Naselli G, Bandala-Sanchez E, Thomas T, Harrison LC, Zhang Y (2016). Regulation of immune cell function by short chain fatty acids. European Journal of Immunology, 46:321-321.
[59] Pluznick J (2014). A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes, 5:202-207.
[60] Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. (2009). GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res, 69:2826-2832.
[61] McCabe L, Britton RA, Parameswaran N (2015). Prebiotic and Probiotic Regulation of Bone Health: Role of the Intestine and its Microbiome. Curr Osteoporos Rep, 13:363-371.
[1] Supplementary data Download
[1] Yuxiao Liao,Zhao Peng,Liangkai Chen,Yan Zhang,Qian Cheng,Andreas K. Nüssler,Wei Bao,Liegang Liu,Wei Yang. Prospective Views for Whey Protein and/or Resistance Training Against Age-related Sarcopenia[J]. Aging and disease, 2019, 10(1): 157-173.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd